TORONTO, Sept. 6, 2018 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX-V: HLS), a specialty pharmaceutical company specializing in central nervous system ("CNS") and cardiovascular markets, announces that it has appointed Mr. Tim Hendrickson, the Company's Vice President, Finance & Administration, to the role of Chief Financial Officer ("CFO"), effective immediately.
"Tim was one of the first employees hired after HLS was founded in 2015, and he has been a valuable member of our leadership team as we have transitioned from a start-up to a publicly-traded company in a short period of time," said Greg Gubitz, CEO of HLS. "Prior to HLS, Tim worked at several publicly-traded companies in the pharmaceutical industry, and we'll look to draw on his experience and expertise as we expand our product portfolio, manage our operational growth and establish ourselves as one of Canada's leading specialty pharmaceutical companies."
Mr. Hendrickson joined HLS in 2015 as Vice President, Finance & Administration. Prior to that, he was Senior Director, Finance, at Cubist Pharmaceuticals Canada, Inc., a specialty pharmaceutical company whose parent company was publicly-traded on NASDAQ and was acquired in 2015. From 2009 – 2014, he was Director, Finance and Business Development, at Warner Chilcott Canada Co., a mid-sized specialty pharmaceutical company whose parent company was also publicly-traded on NASDAQ and was acquired in 2013. From 2003 – 2009, Mr. Hendrickson was Canada Finance Leader at Procter & Gamble Pharmaceuticals Canada Inc., and prior to that, he held a series of progressive financial and leadership roles at Procter & Gamble, Inc. from 1998 – 2003. Mr. Hendrickson has a Bachelor of Commerce degree from the University of Toronto and an MBA from the Rotman School of Management, University of Toronto.
ABOUT HLS THERAPEUTICS INC.
Formed in 2015, HLS is a specialty pharmaceutical company focused on the acquisition and commercialization of late stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE HLS Therapeutics Inc.
For further information: HLS CONTACT INFORMATION: Dave Mason, Investor Relations, HLS Therapeutics Inc., (416) 247-9652, [email protected]; Gilbert Godin, President and Chief Operating Officer, HLS Therapeutics Inc., (484) 232-3400 ext101, [email protected]